NEW YORK, April 18, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Lion Biotechnologies, Inc. (“Lion Biotechnologies” or the “Company”) (Nasdaq:LBIO) in the United States District Court for the Northern District of California on behalf of a class consisting of investors who purchased or otherwise acquired Lion Biotechnologies stock on the open market from November 14, 2013 and April 10, 2017, inclusive (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) Lion Biotechnologies, through its former CEO Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion Biotechnologies to potential investors that purported to be independent from the company when, in fact, they were paid promotions; (2) former CEO Singh engaged a notorious stock promotion firm to pay writers to publish articles about Lion Biotechnologies on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion Biotechnologies was indirectly compensating them for their publications; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than June 13, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Google Secures Pentagon AI Deal for Classified Projects
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 



